Literature DB >> 9580632

delta Opioid receptor subtypes activate inositol-signaling pathways in the production of antinociception.

P Sánchez-Blázquez1, J Garzón.   

Abstract

To analyze the selectivity of delta receptor subtypes to regulate different classes of G proteins, the expression of the alpha-subunits of Gi2, Gi3, Go1, Go2, Gq and G11 transducer proteins was reduced by administration of oligodeoxynucleotides (ODNs) complementary to sequences in their respective mRNAs. Mice receiving antisense ODNs to Gi2 alpha, Gi3 alpha, Go2 alpha and G11 alpha subunits showed an impaired antinociceptive response to all the delta agonists evaluated. An ODN to Go1 alpha specifically blocked the antinociceptive effect of the agonist of delta-1 receptors, [D-Pen2,5]enkephalin (DPDPE), without altering the activity of [D-Ala2]deltorphin II or [D-Ser2]-Leu-enkephalin-Thr (DSLET). In mice treated with an ODN to Gq alpha, the effects of the agonists of delta-2-opioid receptors were reduced, but not those of DPDPE. Thus, Go1 proteins are selectively linked to delta-1-mediated analgesia, and Gq proteins are related to delta-2-evoked antinociception. After impairing the synthesis of Go1 alpha subunits, DPDPE exhibited an antagonistic activity on the antinociception produced by [D-Ala2]deltorphin II. After treatment with ODNs complementary to sequences in Gq alpha or PLC-beta 1 mRNAs, the analgesic capacity of [D-Ala2]deltorphin II was diminished. However, the delta-2-agonist did not alter the antinociceptive activity of DPDPE. An ODN complementary to nucleotides 7 to 26 of the murine delta receptor reduced the analgesic potency of [D-Ala2]deltorphin II, but not that observed for DPDPE. In these mice, [D-Ala2]deltorphin II did not antagonize the effect of DPDPE. These results suggest the existence of different molecular forms of the delta opioid receptor, and the involvement of inositol-signaling pathways in the supraspinal antinociceptive effects of delta agonists.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9580632

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Differential prevention of morphine amnesia by antisense oligodeoxynucleotides directed against various Gi-protein alpha subunits.

Authors:  N Galeotti; C Ghelardini; A Bartolini
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Reciprocal modulation of phospholipase Cbeta isoforms: adaptation to chronic morphine.

Authors:  Sumita Chakrabarti; Nai-Jiang Liu; Alan R Gintzler
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-03       Impact factor: 11.205

3.  Role of signalling molecules in behaviours mediated by the δ opioid receptor agonist SNC80.

Authors:  Isaac J Dripps; Brett T Boyer; Richard R Neubig; Kenner C Rice; John R Traynor; Emily M Jutkiewicz
Journal:  Br J Pharmacol       Date:  2018-02-09       Impact factor: 8.739

Review 4.  Molecular Pharmacology of δ-Opioid Receptors.

Authors:  Louis Gendron; Catherine M Cahill; Mark von Zastrow; Peter W Schiller; Graciela Pineyro
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

5.  Differential G-protein activation by alkaloid and peptide opioid agonists in the human neuroblastoma cell line SK-N-BE.

Authors:  S Allouche; J Polastron; A Hasbi; V Homburger; P Jauzac
Journal:  Biochem J       Date:  1999-08-15       Impact factor: 3.857

6.  Different endogenous opioid effects on delta- and mu-receptor subtypes in antral and duodenal motility of conscious dogs.

Authors:  G E Holle; E Steinbach
Journal:  Dig Dis Sci       Date:  2002-05       Impact factor: 3.199

7.  Protein kinase Cε is required for spinal analgesic synergy between delta opioid and alpha-2A adrenergic receptor agonist pairs.

Authors:  Daniel J Schuster; Kelley F Kitto; Aaron C Overland; Robert O Messing; Laura S Stone; Carolyn A Fairbanks; George L Wilcox
Journal:  J Neurosci       Date:  2013-08-14       Impact factor: 6.167

8.  Opioids drive breast cancer metastasis through the δ-opioid receptor and oncogenic STAT3.

Authors:  Sabrina Tripolt; Heidi A Neubauer; Vanessa M Knab; Dominik P Elmer; Fritz Aberger; Richard Moriggl; Daniela A Fux
Journal:  Neoplasia       Date:  2021-01-16       Impact factor: 5.715

9.  Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine.

Authors:  Javier Garzón; Elena de la Torre-Madrid; María Rodríguez-Muñoz; Ana Vicente-Sánchez; Pilar Sánchez-Blázquez
Journal:  Mol Pain       Date:  2009-03-10       Impact factor: 3.395

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.